Form 4 for ABT Abbott Laboratories
Accepted 2025-02-07 00:00:00 ET · period of report 2025-02-05 · accession 0001415889-25-003394 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-07 | 2025-02-05 | ABT | Ford Robert B | COB AND CEO, Dir | S - Sale+OE | $131.17 | -285.4K | 220.1K | -56% | -$37.43M |
| D | 2025-02-07 | 2025-02-05 | ABT | Ford Robert B | COB AND CEO, Dir | M - OptEx | $38.40 | +285.4K | 505.4K | +130% | +$10.96M |
| D | 2025-02-07 | 2025-02-05 | ABT | Ford Robert B | COB AND CEO, Dir | M - OptEx | $0.00 | -285.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2025-02-05 | S | D | 285,388 | $131.17 | 220,059 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.68 to $131.38, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 2 | Common | Common shares without par value | 2025-02-05 | M | A | 285,388 | $38.40 | 505,447 | D | — | — | |
| 3 | Derivative | Option (right to buy) | 2025-02-05 | M | D | 285,388 | $0.00 | 0 | D | $38.40 · 2019-02-19 to 2026-02-18 | 285,388 Common Shares | (F3) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |